ADHD NICE Guidelines

Guideline on ADHD by NICE

Purpose: The ADHD NICE guidelines address the recognition, diagnosis, and management of ADHD in children, young people, and adults. The primary objective is to enhance the recognition and diagnosis process and elevate the quality of care and support for individuals with ADHD.

Update (September 2019): A modification was made to the recommendation concerning the assessment for individuals commencing ADHD medication. It was indicated that an ECG (electrocardiogram) is not mandatory before initiating stimulants, atomoxetine, or guanfacine, provided the cardiovascular history and examination are standard, and the individual is not on medication that poses an augmented cardiovascular risk. More details can be found in the update information.

Recommendations: The guideline introduces new and updated recommendations on:

• Recognition
• Medication
• Diagnosis

Intended Audience:

• Healthcare professionals
• Commissioners and providers
• Individuals with ADHD, along with their families and caregivers

Current Status (December 2021): As of December 2021, no new evidence has been discovered that would necessitate changes to the recommendations. Further details can be found in the surveillance decision.

Guideline Development Process: The document also provides insights into the process of developing NICE guidelines. This specific guideline serves as an update and replacement for previous NICE guidelines and technology appraisal guidance.